GRIA4 Antibody

What is GRIA4 and why is it important in neuroscience research?

GRIA4 (glutamate receptor, ionotropic, AMPA 4) encodes the GluR4/GluA4 protein, which functions as a subunit of AMPA-type glutamate receptors - the predominant excitatory neurotransmitter receptors in the mammalian brain. These receptors are critical for learning, memory, and neuroplasticity .

GluA4-containing AMPA receptors are particularly important because:

• They play a key role in excitatory neurotransmission

• Binding studies show GluR4 exhibits high specific binding for [3H]AMPA but not [3H]kainate

• GluR4-containing channels are permeable to both Ca²⁺ and Na⁺ ions

• Nociceptors involved in neuropathic pain may be presynaptically modulated by GluR4-containing AMPA receptors

• GRIA4 has been implicated in neurodevelopmental disorders, with de novo variants leading to intellectual disability with or without seizures

GluA4 is highly expressed across several brain regions during adulthood, with expression increasing from early fetal periods .

What are the optimal sample types and experimental conditions for GRIA4 antibody applications?

Antigen Retrieval Recommendations:

• For IHC: Use TE buffer pH 9.0 as primary method

• Alternative method: Citrate buffer pH 6.0

• For CellMask co-localization studies: Use optimized protocol (0.2% Tween-20 for 10 min) to preserve CellMask signal while enabling GluA4 detection

Most GRIA4 antibodies detect endogenous levels of total GRIA4 protein and demonstrate cross-reactivity with human, mouse, and rat samples .

What are the recommended dilutions and protocols for different GRIA4 antibody applications?

Important protocol considerations:

• For co-localization studies with membrane markers: Live cells can be incubated in CellMask (2.5 μl/ml) diluted in Sato medium for 5 min (5% CO₂, 37°C) before fixation

• For ChIP experiments: Fix cells in 1% PFA at room temperature for 10 min before adding 0.125 M glycine

• It is recommended to titrate the antibody in each testing system to obtain optimal results

How can GRIA4 antibodies be used to investigate neurodevelopmental disorders?

GRIA4 has been identified as a target for investigating neurodevelopmental disorders (NDDs) following the discovery of de novo variants that lead to intellectual disability with or without seizures . When designing studies:

• Patient sample considerations:

  • Focus on brain regions with high GRIA4 expression

  • Consider variant-specific differences in GluA4 protein structure when selecting antibodies

  • De novo variants in the highly conserved SYTANLAAF motif (transmembrane protein M3) show more severe phenotypes than variants in extracellular domains

• Functional evaluation approaches:

  • Use GRIA4 antibodies to assess protein expression levels in patient-derived samples

  • Compare wild-type vs. variant GluA4 localization using immunofluorescence

  • Combine with electrophysiology to correlate protein expression with functional changes

• Model systems:

  • CRISPR-Cas9 models (like those established in Xenopus) can be evaluated using antibodies to verify protein expression

  • Immortalized cell lines expressing GRIA4 variants can be assessed for protein trafficking defects

Research shows that pathogenic variants in GRIA4 cause dominant functional effects rather than simple loss-of-function, similar to other glutamate receptor mutations . This suggests antibodies recognizing both wild-type and mutant forms are valuable for comparative studies.

What methods are recommended for studying GRIA4 regulatory mechanisms?

GRIA4 expression is regulated by several mechanisms, including transcription factors like NF-Y. When investigating regulatory mechanisms:

• ChIP-based approaches:

  • ChIP experiments can be used to quantify NF-Yb binding to the Gria4 intronic regulatory region

  • Protocol: Fix cells in 1% PFA (room temperature, 10 min), add 0.125 M glycine, collect in Farnham lysis buffer with protease inhibitors, and sonicate (1 × 10s maximum power)

• Reporter assay systems:

  • The Gria4 intronic regulatory region contains CCAAT sequences whose binding by NF-Yb is regulated by excitotoxicity

  • Reporter constructs containing this regulatory region can be used to study transcriptional regulation

  • RNAi knockdown of NF-Yb alters transcription of such reporter constructs

• Excitotoxicity studies:

  • Treatment with AMPA/cyclothiazide (CTZ) or CTZ alone (50 μM for primary OPCs)

  • Garcinol (10 μM) can be used for gene expression, Western blot, and ChIP experiments

These approaches can help elucidate how GRIA4 expression is regulated in different physiological and pathological conditions, including during excitotoxic events relevant to neurological disorders.

How can researchers distinguish between GRIA4 and other AMPA receptor subunits in experimental settings?

Distinguishing between AMPA receptor subunits requires careful antibody selection and experimental design:

• Antibody epitope considerations:

  • Use antibodies targeting unique regions of GRIA4 not conserved in other AMPA subunits

  • C-terminal and extracellular domain-specific antibodies often provide better specificity

  • Antibodies targeting synthetic peptides corresponding to residues near the C-terminal of human GRIA4 show good specificity

• Cross-reactivity testing:

  • Always include positive controls from tissues with known GluA4 expression (cerebellum shows robust expression)

  • Include negative controls using tissues from knockout models or cells not expressing GluA4

  • Consider using siRNA knockdown to validate antibody specificity

• Co-localization studies:

  • Combine GluA4 antibodies with antibodies against other AMPA receptor subunits

  • For membrane localization: Use CellMask Deep Red with optimized protocols (0.2% Tween-20 for 10 min) that preserve CellMask signal while allowing GluA4 detection

• Experimental design recommendations:

  • When studying heteromeric AMPA receptors, use co-immunoprecipitation with subunit-specific antibodies

  • For functional studies, complement antibody-based approaches with electrophysiology to distinguish subunit-specific contributions

Note that immunoprecipitation studies suggest GRIA1 exists in situ as a pentamer , so consider potential heteromeric complexes when interpreting results.

What is known about GRIA4 genetic variants and their impact on antibody-based studies?

Recent research has identified several pathogenic variants in GRIA4 that should be considered when designing antibody-based studies:

Research implications:

• Variants within the SYTANLAAF motif may affect protein conformation and potentially alter antibody binding

• The p.Arg697Pro variant disrupts the α helix structure and potentially causes local unwinding that interferes with binding between monomers

• Different variants show genotype-phenotype correlation, with milder phenotypes observed in individuals with variants outside the SYTANLAAF motif

When studying these variants, consider:

• Using antibodies targeting regions distant from the mutation sites

• Including wild-type controls in all experiments

• Validating antibody recognition of mutant proteins before proceeding with complex studies

How can GRIA4 antibodies be used to study receptor trafficking and localization?

GluA4-containing AMPA receptors undergo dynamic trafficking that can be studied using specialized antibody-based approaches:

• Membrane vs. intracellular pool distinction:

  • Surface biotinylation followed by Western blotting can quantify membrane-expressed GluA4

  • Immunofluorescence with non-permeabilized vs. permeabilized conditions can distinguish surface from total GluA4

  • For membrane co-localization: Use CellMask Deep Red (2.5 μl/ml in Sato medium for 5 min at 37°C) prior to fixation

• Trafficking dynamics:

  • Pulse-chase experiments with antibodies against extracellular epitopes can track receptor internalization

  • Stimulation protocols (e.g., AMPA/CTZ treatment) can be used to induce receptor trafficking followed by antibody detection

  • Live-cell imaging with fluorescently tagged antibody fragments against extracellular domains can monitor real-time trafficking

• Subcellular localization:

  • Co-staining with synaptic markers can determine synaptic vs. extrasynaptic localization

  • For detailed subcellular analysis, combine GRIA4 antibody staining with super-resolution microscopy techniques

• Experimental design considerations:

  • When fixing cells for immunofluorescence, use PFA fixation followed by permeabilization with 0.2% Tween-20 (10 min) to preserve membrane integrity while allowing antibody access

  • Avoid detergents like Triton-X100 when studying membrane proteins to prevent artificial redistribution

What are the critical controls and validation steps for GRIA4 antibody experiments?

Proper validation is essential for reliable GRIA4 antibody results:

• Positive controls:

  • Rat brain tissue, mouse brain tissue, and mouse cerebellum tissue show robust GRIA4 expression

  • Human brain tissue with known GRIA4 expression patterns

  • Cell lines transfected with GRIA4 expression constructs

• Negative controls:

  • Primary antibody omission

  • Isotype control (Rabbit IgG)

  • GRIA4 knockout or knockdown samples

  • Pre-absorption with immunizing peptide (when available)

• Validation methods:

  • Western blot should detect a band at approximately 101 kDa

  • Immunohistochemistry should show expected expression pattern in brain regions

  • RNA expression data should correlate with protein detection

  • Multiple antibodies targeting different epitopes should show similar patterns

• Cross-reactivity assessment:

  • Test for cross-reactivity with other AMPA receptor subunits (GluA1-3)

  • Confirm species reactivity matches manufacturer claims

  • For antibodies with multiple claimed applications, validate each application separately

Additional recommendations include performing titration experiments for each application and including relevant knockdown controls when available.

What are the optimal storage and handling conditions for GRIA4 antibodies?

Proper storage and handling are critical for maintaining antibody performance:

Handling recommendations:

• Avoid repeated freeze-thaw cycles by preparing appropriately sized aliquots

• Centrifuge briefly before opening to collect all liquid at the bottom of the vial

• Handle with clean pipette tips to avoid contamination

• For antibodies containing sodium azide, be aware of potential reaction with lead and copper in plumbing systems

Following these guidelines will help maintain antibody performance and extend shelf life for long-term research projects.

What troubleshooting approaches are recommended for common issues with GRIA4 antibody applications?

Advanced troubleshooting:

• For membrane protein detection issues, try using a gentler permeabilization protocol (0.2% Tween-20 for 10 min)

• For co-localization with membrane markers, CellMask Deep Red (2.5 μl/ml) can be used with this optimized protocol

• If experiencing high background in ChIP experiments, improve sonication (1 × 10s maximum power) and use appropriate controls

How can researchers optimize GRIA4 antibody protocols for different neural cell types?

Different neural cell types require specialized approaches for optimal GRIA4 detection:

• Neurons:

  • Primary cultures: Fix with 4% PFA for 15-20 minutes at room temperature

  • Co-stain with neuronal markers (e.g., MAP2, NeuN) to confirm neuronal identity

  • Use longer permeabilization (0.2% Triton X-100, 10 minutes) for access to intracellular epitopes

• Oligodendrocytes:

  • For Oli-neu cells: Use cell densities of 1 × 10^4 cells/well

  • Reduce fixation, blocking, and secondary antibody incubation steps to 20 min, 1 hr, and 1 hr, respectively

  • Co-stain with oligodendrocyte markers to confirm cell identity

• Astrocytes:

  • May require stronger permeabilization due to complex morphology

  • Co-stain with GFAP or other astrocyte markers

  • Background can be higher; optimize blocking conditions

• Cell lines vs. primary cultures:

  • Primary cultures typically show physiological expression levels

  • Cell lines may require antibody dilution optimization

  • For ChIP experiments with Oli-neu cells, plate at 1 × 10^6 cells in T25 flasks

When studying GluA4 in different neural populations, combine antibody staining with cell type-specific markers to ensure proper identification and characterization of expression patterns.

How are GRIA4 antibodies being used in neurological and psychiatric disorder research?

GRIA4 has been implicated in several neurological and psychiatric disorders, making it an important target for research:

• Neurodevelopmental disorders:

  • De novo variants in GRIA4 lead to intellectual disability with or without seizures and gait abnormalities

  • GRIA4 antibodies can assess protein expression and localization in patient samples or disease models

  • Antibodies targeting specific variants can help characterize pathogenic mechanisms

• Psychiatric disorders:

  • GRIA4 has been associated with nicotine dependence and major depression comorbidity

  • Gene co-expression studies reveal that genes co-expressed with GRIA4 are enriched in mental disorders, depression, bipolar disorder, and anxiety disorder

  • Antibodies can help map expression changes in affected brain regions

• Experimental approaches:

  • For patient-derived samples: Use optimized IHC protocols with TE buffer pH 9.0 for antigen retrieval

  • For animal models: Combine immunohistochemistry with behavioral assessments

  • For genetic studies: Use antibodies to validate protein-level consequences of identified variants

GRIA4 is primarily expressed in human brain, with expression increasing from early fetal periods to adulthood . This developmental pattern makes it particularly relevant for studying neurodevelopmental disorders.

What are the most effective approaches for studying GRIA4 in the context of excitotoxicity?

Excitotoxicity involves excessive glutamate receptor activation and is implicated in numerous neurological conditions. GRIA4 antibodies can be used to study this process:

• Experimental protocols:

  • Treatment paradigms: AMPA/cyclothiazide (CTZ) or CTZ alone (50 μM for primary OPCs)

  • Garcinol (10 μM) can be used in gene expression, Western blot, and ChIP experiments

  • Concentrations >10 μM may cause cell detachment and death, so careful titration is necessary

• Mechanistic investigations:

  • NF-Y-dependent regulation of GRIA4: Excitotoxicity-induced alterations in NF-Yb binding are associated with changes in GRIA4 transcription

  • ChIP experiments can quantify NF-Yb binding to the Gria4 intronic regulatory region

  • Protocol: Fix cells in 1% PFA (10 min, room temperature), add 0.125 M glycine, collect in Farnham lysis buffer with protease inhibitors, and sonicate

• Protein expression and localization:

  • Use antibodies to track changes in total GluA4 levels during excitotoxic events

  • Membrane vs. cytoplasmic fractionation with Western blotting can assess trafficking changes

  • Immunofluorescence before and after excitotoxic stimuli can reveal subcellular redistribution

Research shows that NF-Y networks may be potential pharmacological targets for promoting oligodendrocyte precursor cell survival during excitotoxic events .

How can GRIA4 antibodies be used in combination with electrophysiology to study receptor function?

Integrating antibody-based techniques with electrophysiology provides powerful insights into GRIA4 function:

• Correlative approaches:

  • Use immunofluorescence to map GluA4 expression in specific neurons followed by targeted patch-clamp recording

  • Quantify surface vs. total GluA4 expression and correlate with AMPA receptor-mediated currents

  • Compare wild-type vs. mutant GluA4 expression and corresponding functional changes

• Experimental design considerations:

  • For brain slice preparations: Validate antibody penetration depth before correlating with recorded neurons

  • For cultured neurons: Use live-labeling with antibodies against extracellular epitopes before recording

  • For heterologous expression systems: Confirm protein expression with antibodies before functional recording

• Advanced approaches:

  • Combine antibody-based optical sensors with electrophysiology for simultaneous monitoring

  • Use protein crosslinking with antibodies to trap specific receptor conformational states for functional studies

  • Employ antibody-based receptor tagging for single-particle tracking combined with electrophysiology

These integrated approaches are particularly valuable for studying GRIA4 variants associated with neurodevelopmental disorders, as they can directly link protein expression/localization changes to functional consequences.